[go: up one dir, main page]

AR131690A1 - COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS - Google Patents

COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS

Info

Publication number
AR131690A1
AR131690A1 ARP240100175A ARP240100175A AR131690A1 AR 131690 A1 AR131690 A1 AR 131690A1 AR P240100175 A ARP240100175 A AR P240100175A AR P240100175 A ARP240100175 A AR P240100175A AR 131690 A1 AR131690 A1 AR 131690A1
Authority
AR
Argentina
Prior art keywords
nav
kits
compositions
treatment methods
phenolic compounds
Prior art date
Application number
ARP240100175A
Other languages
English (en)
Inventor
Gabriela Barreiro
De Santana Danilo Pereira
Monteiro Jlia Lammoglia
Gamba Luis Eduardo Reina
Fraga Carlos Alberto Manssour
Lacerda Barreiro Eliezer Jesus De
Lima Ldia Moreira
Original Assignee
Eurofarma Laboratorios S A
Univ Federal Do Rio De Janeiro Ufrj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurofarma Laboratorios S A, Univ Federal Do Rio De Janeiro Ufrj filed Critical Eurofarma Laboratorios S A
Publication of AR131690A1 publication Critical patent/AR131690A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C07C15/12—Polycyclic non-condensed hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
    • C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos fenólicos bloqueadores de Nav 1.7 y/o Nav 1.8. Más específicamente, la presente invención describe fenoles que comprenden la fórmula (1), en la cual los sustituyentes R¹ a R¹² son seleccionados independientemente de los grupos definidos en la memoria descriptiva, así como sus procesos de obtención, composiciones que comprenden al menos uno de los mismos compuestos, usos, métodos de tratamiento para tratar o prevenir patologías relacionadas al dolor y kits. La presente invención pertenece a los campos de la química medicinal, síntesis orgánica, así como en el tratamiento de enfermedades relacionadas con el dolor.
ARP240100175A 2023-01-30 2024-01-25 COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS AR131690A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363482211P 2023-01-30 2023-01-30

Publications (1)

Publication Number Publication Date
AR131690A1 true AR131690A1 (es) 2025-04-23

Family

ID=92145550

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100175A AR131690A1 (es) 2023-01-30 2024-01-25 COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS

Country Status (6)

Country Link
EP (1) EP4660183A1 (es)
AR (1) AR131690A1 (es)
CO (1) CO2025011717A2 (es)
MX (1) MX2025008865A (es)
UY (1) UY40625A (es)
WO (1) WO2024159286A1 (es)

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
SE0104330D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
AU2003234464B2 (en) * 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
EP1510207A4 (en) * 2002-06-05 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC MEDICAMENT AGAINST DIABETES
TW200410671A (en) * 2002-06-05 2004-07-01 Inst Med Molecular Design Inc Medicines for inhibiting the activation of AP-1
CN1658854A (zh) * 2002-06-05 2005-08-24 株式会社医药分子设计研究所 免疫关联蛋白激酶抑制剂
WO2003103665A1 (ja) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 抗アレルギー薬
KR20060019558A (ko) * 2003-05-27 2006-03-03 바스프 악티엔게젤샤프트 유해 곤충류 및 거미류의 방제를 위한 히드라존 유도체
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
CN100355748C (zh) * 2004-09-20 2007-12-19 中国人民解放军军事医学科学院毒物药物研究所 芳酰肼类化合物及其用于制备免疫抑制剂的用途
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US20100035932A1 (en) * 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
CA3013000C (en) * 2008-12-19 2022-12-13 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
CA2771472A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US8518968B2 (en) * 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
DK2835131T3 (en) * 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
WO2012129562A2 (en) * 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2013123071A1 (en) * 2012-02-13 2013-08-22 Cleave Biosciences, Inc. Methods and compositions for jamm protease inhibition
CN103880707B (zh) * 2012-12-19 2016-04-13 上海交通大学医学院 Stat3小分子抑制剂及其应用
EP2951168B1 (en) 2013-01-31 2017-01-04 Vertex Pharmaceuticals Incorporated Quinoline and quinoxaline amides as modulators of sodium channels
AU2014212509B2 (en) 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
SG11201600082VA (en) 2013-07-10 2016-02-26 Vertex Pharma Fused piperidine amides as modulators of ion channels
WO2015048547A2 (en) * 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US9163042B2 (en) 2013-12-13 2015-10-20 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
CN105481765A (zh) * 2015-04-15 2016-04-13 江苏艾凡生物医药有限公司 一类用于治疗心力衰竭的酰腙类衍生物
JP2017001991A (ja) 2015-06-11 2017-01-05 大日本住友製薬株式会社 新規ベンズオキサゾロン化合物
JP2019514879A (ja) 2016-04-20 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アシルスルホンアミドＮａＶ１．７阻害剤
KR102714561B1 (ko) 2017-05-16 2024-10-10 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
MX393803B (es) 2017-06-20 2025-03-24 Raqualia Pharma Inc Derivados de amida como bloqueadores de nav1.7 y nav1.8
TW201920081A (zh) 2017-07-11 2019-06-01 美商維泰克斯製藥公司 作為鈉通道調節劑的羧醯胺
WO2020023802A1 (en) * 2018-07-25 2020-01-30 City Of Hope Parg inhibitors and method of use thereof
US20220112157A1 (en) * 2018-09-05 2022-04-14 The University Of British Columbia Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith
GEP20237568B (en) 2018-11-02 2023-11-27 Merck Sharp & Dohme Llc 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2020210428A1 (en) * 2019-04-09 2020-10-15 Baylor College Of Medicine Novel inhibitors of flavivirus protease for prevention and treatment of zika, dengue and other flavivirus infections
WO2020209932A1 (en) * 2019-04-12 2020-10-15 University Of Puerto Rico Compounds with antimalarial activity
CN111925357B (zh) * 2019-05-13 2023-06-06 中国科学院昆明植物研究所 一种酰腙类化合物及其药物组合物和其应用
CN110128343A (zh) * 2019-06-18 2019-08-16 四川省人民医院 一种酰肼类化合物
BR112021026395A2 (pt) 2019-06-27 2022-02-08 Glaxosmithkline Ip Dev Ltd Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8
AR126669A1 (es) * 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
UY40051A (es) * 2021-12-01 2023-05-31 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES SELECTIVOS DE HDAC6, SUS PROCESOS DE...(ver adjuntos)

Also Published As

Publication number Publication date
CO2025011717A2 (es) 2025-09-08
WO2024159286A1 (pt) 2024-08-08
UY40625A (es) 2024-07-31
EP4660183A1 (en) 2025-12-10
MX2025008865A (es) 2025-10-01

Similar Documents

Publication Publication Date Title
CL2020002511A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CU24643B1 (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47
MX2020011565A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
CO2018004964A2 (es) Compuestos útiles como inmunomoduladores
UY27924A1 (es) Compuestos tipo diarilureas fluoradas
AR132340A1 (es) Compuestos tricíclicos para el tratamiento de cáncer
CO2024002075A2 (es) Compuestos n-acilhidrazónicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de estos y kits
CO2025000185A2 (es) Derivados de anilino-pirazol, composiciones y métodos de estos
DOP2025000213A (es) [1,3]tiazolo[4,5-d]-pirimidin-7-onas como inhibidores de la nox4
CO2024015229A2 (es) Compuestos y usos de estos
BR112022017099A2 (pt) Composto, composição farmacêutica, método para inibição de ripk1, método para tratamento de uma doença mediada por ripk1 e método para tratamento de lesão no snc
AR132992A1 (es) Agonistas de trem2
AR131690A1 (es) COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS
UY39882A (es) COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
UY40629A (es) Amidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos....
AR130483A1 (es) Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
AR131658A1 (es) Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y sus kits
UY40627A (es) Compuestos arilpiridinas bloqueadores de nav 1.7 y/o nav 1.8, sus procesos de obtención...
AR131716A1 (es) HIDROXAMATOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS
AR134419A1 (es) Compuestos que inhiben la quinasa tipo polo 4
AR134259A1 (es) Compuestos de pirimidina bicíclicos, métodos y usos de estos
MX2024007069A (es) Inhibidores de la interacción menina-mll.
AR131685A1 (es) 1h-pirazol-4-carboxamidas sustituidas como inhibidores de sarm1
AR132459A1 (es) Inhibidores de kras de pirrolidina
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras